Results 21 to 30 of about 27,037 (216)

Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium.

PLoS Biology, 2020
The antimicrobial resistance crisis has persisted despite broad attempts at intervention. It has been proposed that an important driver of resistance is selection imposed on bacterial populations that are not the intended target of antimicrobial therapy.
Clare L Kinnear, Elsa Hansen, Valerie J Morley, Kevin C Tracy, Meghan Forstchen, Andrew F Read, Robert J Woods   +6 more
doaj   +2 more sources

Daptomycin resistance of Corynebacterium jeikeium due to pgsA gene mutation acquired during daptomycin treatment in a patient with infective endocarditis

International Journal of Infectious Diseases
Daptomycin is an alternative agent for invasive infections caused by Corynebacterium species in patients with intolerance to vancomycin. Although it has recently been recognized that treatment failure with daptomycin due to the emergence of resistant ...
Makoto Inada, Kohji Komori, Sohei Harada, Shinya Yamamoto, Koh Okamoto, Ayano Nakazato, Yoshimi Higurashi, Shuhei Matsumoto, Junji Tokushige, Arika Shimura, Takeya Tsutsumi   +10 more
doaj   +2 more sources

DAPTOMYCIN ANALOGUES AND A METHOD FOR THE PREPARATION OF DAPTOMYCIN OR A DAPTOMYCIN ANALOGUE [PDF]

, 2015
A method for the synthesis of daptomycin or a daptomycin analogue is carried out on a resin to form a linear precursor followed by a serine ligation macrocyclization in solution. Daptomycin analogues can differ from daptomycin by substitution of amino acids residues and/or deletion or addition of amino acid residues.
openaire   +2 more sources

Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin

Nature, 2023
Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health1. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode of action2, but for which resistance has ...
A. M. Turner, Lucy Li, I. Monk, Jean Y. H. Lee, D. Ingle, Stephanie Portelli, N. Sherry, Nicole Isles, T. Seemann, Liam K. R. Sharkey, Calum J. Walsh, Gavin E Reid, Shuai Nie, Bart A. Eijkelkamp, Natasha E. Holmes, Brennan Collis, S. Vogrin, A. Hiergeist, D. Weber, A. Gessner, Ernst Holler, David B. Ascher, Sebastián Duchêne, Nichollas E. Scott, T. Stinear, J. Kwong, C. Gorrie, B. Howden, Glen P. Carter   +28 more
semanticscholar   +1 more source

The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis

Frontiers in Medicine, 2021
Background and Aim: The predominant species of the Enterococcus, Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium) cause great variety of infections.
M. Dadashi, Parastoo Sharifian, Nazila Bostanshirin, Bahareh Hajikhani, N. Bostanghadiri, Nafiseh Khosravi-Dehaghi, A. van Belkum, D. Darban-Sarokhalil   +7 more
semanticscholar   +1 more source

Bacterial cell membranes and their role in daptomycin resistance: A review

Frontiers in Molecular Biosciences, 2022
Lipids play a major role in bacterial cells. Foremost, lipids are the primary constituents of the cell membrane bilayer, providing structure and separating the cell from the surrounding environment.
April H. Nguyen, Kara S. Hood, E. Mileykovskaya, William R. Miller, T. Tran   +4 more
semanticscholar   +1 more source

A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category

Infectious Diseases and Therapy, 2023
Introduction Daptomycin doses 8–12 mg/kg are recommended for susceptible dose-dependent Enterococcus species. However, data remain limited on safety outcomes of such dosing, compared to standard 4–6 mg/kg dosing.
Ming M. Zhang, Ryan W. Stevens, Jennifer L. Adema, Kristin C. Mara, Audrey N. Schuetz, Aaron J. Tande, Christina G. Rivera   +6 more
doaj   +1 more source

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. [PDF]

PLoS ONE, 2016
Our objective was to study the pharmacodynamics of daptomycin in the presence of varying concentrations of human serum (HS) in vitro to quantify the fraction of daptomycin that is 'active'.
Samira M Garonzik, Justin R Lenhard, Alan Forrest, Patricia N Holden, Jϋrgen B Bulitta, Brian T Tsuji   +5 more
doaj   +1 more source

Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis

BMC Microbiology, 2020
Background Viridans group streptococci of the Streptococcus mitis-oralis subgroup are important endovascular pathogens. They can rapidly develop high-level and durable non-susceptibility to daptomycin both in vitro and in vivo upon exposure to daptomycin.
Allison Parrett, Joseph M. Reed, Stewart G. Gardner, Nagendra N. Mishra, Arnold S. Bayer, Robert Powers, Greg A. Somerville   +6 more
doaj   +1 more source

Removal of peptidoglycan and inhibition of active cellular processes leads to daptomycin tolerance in Enterococcus faecalis.

PLoS ONE, 2021
Daptomycin is a cyclic lipopeptide antibiotic used in the clinic for treatment of severe enterococcal infections. Recent reports indicate that daptomycin targets active cellular processes, specifically, peptidoglycan biosynthesis. Within, we examined the
Rachel D Johnston, Brittni M Woodall, Johnathan Harrison, Shawn R Campagna, Elizabeth M Fozo   +4 more
doaj   +1 more source